460 Totten Pond Rd.
11 articles about Upstream Bio
Upstream Bio Announces Dosing of First Patients in a Phase 2 Clinical Trial of Verekitug (UPB-101) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Upstream Bio today announced the dosing of the first patients in a Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Advancements in asthma biologics spell future hope for patients with severe asthma.
Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, announced positive interim results in its Phase 1b clinical study of UPB-101, a thymic stromal lymphopoietin receptor inhibitor.
Seed and Series A funding are set to drop this year as investors are looking for more advanced, less risky deals, according to an industry analysis from HSBC.
Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases
Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases.
The company said Thursday it has closed $200 million in Series B financing—on top of last year’s $200 million Series A haul—to help initiate a registrational Phase II study for its lead candidate UPB-101.
Upstream Bio to Present New Clinical Data from Phase 1 Study of UPB-101 at the American Thoracic Society (ATS) International Conference
Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced an upcoming poster presentation featuring new clinical data from its Phase 1 clinical study of UPB-101 at the American Thoracic Society (ATS) International Conference, happening May 19-24 in Washington, DC.
Upstream Bio today announced the appointment of Dr. Marcella Ruddy to its Board of Directors.
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.
After reaching a record high in 2021, venture capital dollars have tailed off in the biopharma industry in 2022. That said, a few biopharma hotbeds have still seen sizeable launch rounds.
Upstream Bio is focusing its efforts on an experimental treatment for severe asthma licensed from Astellas Pharma.